Carl Zeiss Meditec AG Q4 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Scott Bardo - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : So first question, please. I wonder if you could help provide a little bit more granularity about the consumables business and the various different segments of it. Can you help understand -- us understand what the growth of your IOL business was for the last fiscal and also the growth of then the refractive consumable business? Perhaps if you would kind of update us on what's your current installed bases for the Visumax system and

Question: Scott Bardo - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Understood. And perhaps just one follow-up, if I may. I think, actually, on the occasion of this call last year, this time last year, we looked at a pretty impressive series of new product launches from instruments and capital that Carl Zeiss was in the market with. We discussed about the potential for additional innovations in the consumable business, where, arguably, you've had less launches in recent times. Can you help us understand, is there any meaningful and obvious momentum with respect to new innovations in your consumable business that we should be expecting?

Question: Scott Bardo - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Just some questions on the capital side of your business, please. Can you help us understand, please, the order trend in microsurgery or, more broadly, your capital business throughout the course of the last fiscal? Just trying to understand whether it declined more than the revenues or fared better than your revenue development this year and confidence then into -- in the upcoming year. So that would be helpful. Second question, please, and I don't know if it's too early here, but obviously, hospitals have had some challenges to deal with this year as well, allocating budgets in different ways. Have you had any discussion so far with hospitals about the way that they think about allocating budgets into next year? Are there certain buckets of capital not served by Carl Zeiss Meditec that will take priority in your opinion? Or is it likely that your sorts of solutions will be prioritized in this sort of allocation of budget? And third question, please. We note that one of your competitors, Alcon, has been moving more notably into biometry and highlighting quite some momentum in that field. I know that you're a leader -- a global leader in this space. I just wonder if you could comment on whether the competitive dynamic is intensifying notably.